Retinitis Pigmentosa clinical trials

Explore recruiting retinitis pigmentosa clinical trials.

Recruiting retinitis pigmentosa studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Retinitis Pigmentosa trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

NAC Attack, A Phase III, Multicenter, Randomized, Parallel, Double Masked, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral N-Acetylcysteine in Patients with Retinitis Pigmentosa

Netherlands, Austria, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1/2a, Open-Label, Non-Randomized, Dose-Escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects with Retinitis Pigmentosa.

France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

PIGMENT – PDE6A gene therapy for retinitis pigmentosa

Germany

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A phase 1/2, open-label, safety, tolerability and preliminary efficacy study of implantation into one eye of hESC-derived RPE (Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (RPE)) in patients with retinitis pigmentosa due to monogenic mutation

France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Randomized, Controlled, Masked, Multi-center Study Evaluating the Efficacy, Safety, and Tolerability of Two Doses of AGTC-501 Compared to an Untreated Control Group in Male Participants with X-linked Retinitis Pigmentosa

Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Two-Year Double-masked, Randomized, Sham-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects with Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of the USH2A Gene

Netherlands, Germany, France, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Retinitis Pigmentosa trials by city

Retinitis Pigmentosa in Toronto Retinitis Pigmentosa in Vancouver Retinitis Pigmentosa in Montreal Retinitis Pigmentosa in Calgary Retinitis Pigmentosa in Edmonton Retinitis Pigmentosa in Ottawa Retinitis Pigmentosa in Winnipeg Retinitis Pigmentosa in Quebec City Retinitis Pigmentosa in Hamilton Retinitis Pigmentosa in Kitchener Retinitis Pigmentosa in London Retinitis Pigmentosa in Halifax Retinitis Pigmentosa in New York Retinitis Pigmentosa in Los Angeles Retinitis Pigmentosa in Chicago Retinitis Pigmentosa in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease